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According to the definition proposed by the International League of Associations for Rheumatology (ILAR), juvenile idiopathic
arthritis (JIA) is defined as an arthritis of unknown etiology, starting under 16 years of age and lasting for at least 6 weeks, once other
known conditions have been excluded. JIA represents the most common chronic rheumatic disease of childhood and is considered
an important cause of short- and long-term acquired disability in children. It is currently estimated that psoriatic JIA represents
up to 10% of all JIA subtypes, and chronic uveitis may occur in 10 to 15% of children with psoriatic JIA. In this report we describe
a case of psoriatic JIA complicated by uveitis, in a child failing previous treatments with nonsteroidal anti-inflammatory drugs,
methotrexate, and etanercept. Finally, adalimumab was prescribed, which led to sustained clinical remission in both arthritis and
uveitis.
1. Background
According to the definition proposed by the International
League of Associations for Rheumatology (ILAR), juvenile
idiopathic arthritis (JIA) is defined as an arthritis of unknown
etiology, starting before 16 years of age, and lasting for at least
6 weeks, once other known conditions have been excluded
[1]. JIA represents the most common chronic rheumatic
disease of childhood and is considered an important cause of
short- and long-term acquired disability in children [2]. JIA
encompasses seven different subcategories based on the pre-
dominant clinicalmanifestations and laboratory features seen
in the first 6months of disease. Its prevalence is unknown and
varies considerably among populations, depending on race,
immunogenetic susceptibility, and environmental influences.
Currently, the annual incidence of JIA is estimated at around
100 new cases per 1,000,000 population [3].
JIA is considered an autoimmune disease, potentially
resulting from an abnormal immunologic response caused
or triggered by environmental factors such as infection
or trauma in a genetically predisposed subject. Adaptive
immune activation against self-epitopes has been suggested,
and a typical synovial membrane inflammation has been
observed [4–6]. The synovia shows pronounced hyperplasia
of the lining layer, along with an exuberant infiltration of the
sublining layer with mononuclear cells, including memory T
cells, B cells, macrophages, dendritic cells, and plasma cells
[2].
Psoriatic JIA represents up to 10% of all JIA subtypes
and has a predilection for females. Anti-nuclear antibodies
(ANAs) are positive in more than 50% of affected patients.
According to the ILAR classification, psoriatic JIA has to
satisfy the criteria shown in the following [1].
ILAR Inclusion and Exclusion Criteria for Psoriatic JIA [1]:
ILAR Inclusion Criteria. Arthritis is associated with psoriasis
or two of the following:
(1) dactylitis,
(2) nail pitting,
(3) onycholysis,
(4) psoriasis in a first degree relative.
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ILAR Exclusion Criteria. Consider the following:
(1) arthritis in HLA-B27-positive males beginning after
the age of 6 years,
(2) ankylosing spondylitis, enthesitis-related arthritis,
sacroiliitis with inflammatory bowel disease, Reiter’s
syndrome, acute anterior uveitis, or history of one of
these in a first-degree relative,
(3) presence of IgM rheumatoid factor on at least two
occasions more than 3 months apart,
(4) presence of systemic arthritis.
Arthritis precedes the psoriatic cutaneous manifestations
in more than 60% of cases, sometimes years earlier [7],
and usually presents in an asymmetric oligoarthritis pattern.
Monoarthritis is relatively common at the onset, with isolated
involvement of knee and small joints of hands and feet.
Without effective therapy, progression to the polyarticular
form occurs in 60–80% of children. Dactylitis, swelling of
the whole digit (i.e., extending beyond the borders of the
joint), with the subsequent typical “sausage digit” appear-
ance, is observed in 20–40% of affected patients. Cutaneous
manifestations are often represented by nail pitting (diffused
or confluent multiple pits localized on the nail surface),
discoloration, and onycholysis, involving all or part of the
nail.
Younger ANA positive patients are at highest risk of
developing ocular complications such as chronic uveitis,
which may occur in 10 to 15% of children with psoriatic JIA
[8].
2. Case Presentation
At the age of 2 years and 6 months, a Caucasian male with
no significant past medical or family history presented at our
emergency department with progressive painful swelling of
the left knee, along with morning stiffness and limited range
of motion. Physical examination revealed arthritis of the left
knee, and laboratory findings showed a mild increase in C-
reactive protein (CRP) level and erythrocyte sedimentation
rate (ESR). An ultrasound confirmed intra-articular effusion.
Symptomatic therapy with a nonsteroidal anti-inflammatory
drug (NSAID) was prescribed, and the child was referred to
our rheumatology unit for further investigation and followup.
Our first evaluation confirmed both previous clinical and
laboratory findings. The ANA titre was positive (1 : 320),
HLA-B27 was negative, and slit lamp examination showed
no signs of uveitis. One month later, while still receiving
NSAIDs, three additional joints were active (right knee,
right ankle, and fourth right proximal interphalangeal joint),
while ophthalmologic examination with slit lamp revealed
anterior chamber inflammation of the right eye. Due to the
progressive and additive course of joint disease together with
the eye involvement, methotrexate (MTX; 15mg/m2) was
administered in association with the NSAIDs therapy. Sus-
tained clinical benefit was rapidly obtained, with a complete
resolution of articular manifestations and uveitis, associated
with normalization of inflammatory parameters. After 2 years
of clinical remission on this therapy, psoriasiform lesions
appeared on elbows and knees, and a diagnosis of psoriasis
was made. A few months later, while still receiving MTX, a
new episode of arthritis involving both knees and the right
ankle occurred. Laboratory findings again showed increased
ESR and CRP levels, and slit lamp examination revealed a
new flare of uveitis. Considering the poor clinical control
achieved with the current medications, we decided to add
a biologic modifier to MTX therapy, and so etanercept, a
tumour necrosis factor (TNF) inhibitor, was administered
subcutaneously at the dose of 0.4mg/Kg twice weekly. Clin-
ical remission was rapidly obtained, with absence of joint
swelling and uveitis flares. In consideration of the persistent
clinical benefit reached through the combined therapy, we
decided to stop the MTX administration after 1 year from
its introduction due to persistent elevation of liver functions
tests. Six months later, slit lamp exam revealed again new
signs of anterior chamber uveitis activity, this time affecting
both eyes. After one month, a severe arthritis flare occurred,
with an aggressive polyarticular course. In consideration of
the lack of control obtained through the Enbrel administra-
tion and according to the current literature, which showed
the efficacy and safety of adalimumab in the treatment of
uveitis in JIA patients who failed previous therapies, we
then decided to switch from etanercept to subcutaneous
adalimumab (Humira, AbbVie Inc. Chicago, IL), which was
administered in monotherapy at 24mg/m2 every other week.
After 3 months’ followup, the child experienced complete
remission of arthritis and uveitis, which has lasted for two
years (up to the latest visit). No adverse reactions occurred
during treatment.
3. Discussion
We present a case of psoriatic JIA complicated by uveitis, fail-
ing previous treatments with NSAID, MTX, and etanercept.
American College of Rheumatology (ACR) JIA treatment
recommendations are based on a step-up approach, requiring
the subsequent use of drugs with greater power once the
previous treatment has failed [9]. Regarding systemic therapy,
NSAIDs are prescribed as first-line treatment of symp-
toms, followed by disease-modifying antirheumatic drugs
(DMARDs), such asMTX, and low-dose oral corticosteroids,
if needed, for short periods. In case of an incomplete response
after 3–6 months, biologic agents, beginning with an anti-
TNF𝛼 agent, are strongly recommended.
In this case, etanercept was initially effective in control-
ling the disease, used in combinationwithMTX for 1 year, and
then as monotherapy for 6 months. Unfortunately, 6 months
after MTX discontinuation new signs of anterior chamber
inflammation were seen in both eyes, and an impressive
flare of polyarticular arthritis was observed soon after. These
worsening clinical manifestations prompted the switch from
etanercept to another anti-TNF𝛼, adalimumab, according to
recent compelling evidence [10, 11]. Our experience has been
positive, with adalimumab leading to a complete and long-
lasting remission of disease. Adalimumab is a fully human
subcutaneously administered IgG anti-TNF antibody that
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binds to TNF𝛼, preventing it from activating TNF receptors,
thus downregulating the inflammatory reactions associated
with several autoimmune diseases.
Experience of adalimumab therapy in JIA comes from
the controlled study published by Lovell et al., which showed
efficacy and safety in JIA [10]. The results of a recent
Japanese multicentre study confirmed adalimumab efficacy
in reducing disease activity and maintaining response in
paediatric patients with polyarticular JIA [12]. Adalimumab
is approved by theU.S. Food andDrugAdministration (FDA)
for the treatment of rheumatoid arthritis (RA), JIA, anky-
losing spondylitis (AS), psoriatic arthritis (PsA), psoriasis,
and Crohn’s disease. The recommended dose is 24mg/m2
(maximum dose 40mg), given subcutaneously every other
week [13, 14]. Adalimumab is the second TNF antagonist to
receive FDA approval for treatment of moderate to severe
active polyarticular JIA in patients 4 years and older [15, 16].
Adverse events are rare, mainly consisting of injection site
reactions and respiratory tract infections.
The current literature about the use of adalimumab in
children with JIA and uveitis who have failed previous
therapies reports excellent results. In 2011, Kotaniemi and col-
leagues, expanding a previous reported cohort [17], showed
a significant disease improvement with adalimumab in 94
patients with persistent active JIA and/or associated uveitis
[18]. In another study, 39 patients with JIA and refractory
uveitis were treated with adalimumab, which, again, proved
to be well tolerated and helpful in decreasing ocular inflam-
matory activity [19].
We previously reported that adalimumab is superior
to infliximab in maintaining disease remission in children
with refractory chronic uveitis [20]. Moreover, a German
study showed better control of uveitis with adalimumab
compared with etanercept in a retrospective analysis of data
from 18 children and young adults [21]. Finally, a French
case series showed that development of new-onset uveitis in
patients receiving anti-TNF𝛼 therapy for rheumatic diseases
was higher with etanercept compared with adalimumab or
infliximab [22]; in our case, the possibility that etanercept
could have triggered anterior chamber ocular activity cannot
be excluded.
In conclusion, our experience with adalimumab has been
positive, leading to the control of both arthritis and uveitis in
a child with psoriatic JIA complicated by uveitis, which was
resistant to previous treatments withNSAIDs,DMARDs, and
initial TNF inhibitor therapy etanercept.
Key Points
(i) JIA is the most common chronic rheumatic disease
of childhood, and psoriatic JIA represents up to 10%
of all JIA subtypes, with chronic uveitis occurring in
10–15% of children with psoriatic JIA.
(ii) In this case of psoriatic JIA with uveitis, adalimumab
treatment brought about complete and sustained
remission in both arthritis and uveitis in a child failing
previous treatments with NSAIDs, MTX, and anti-
TNF𝛼 therapy.
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